case_images: PMC10699832_01
case_images: Anatomical pathology samples of hematoxylin-eosin staining. a Tumor well demarcated with well-defined borders, not encapsulated (hematoxylin-eosin staining. x2). b Oval cells with a clear eosinophilic and poorly demarcated cytoplasm. The cells present oval nuclei, with isomorphous thin chromatin and eosinophilic micronuclei. The cells are growing in nests, separated by thin fibrous tracts (hematoxylin-eosin staining. x10).
case_images: cro-2023-0016-0001-534935_F01.jpg
case_images: PMC10699832_01_cro-2023-0016-0001-534935_F01.jpg
case_images: F1
case_images: An anatomopathological review revealed that the patient had a tumor with oval cells with a clear eosinophilic and poorly demarcated cytoplasm, growing in nests separated by thin fibrous tracts (Fig. 1).
case_images: Immunohistochemistry staining is diffusely positive for S100 (a) and SOX10 (b).
case_images: cro-2023-0016-0001-534935_F02.jpg
case_images: PMC10699832_01_cro-2023-0016-0001-534935_F02.jpg
case_images: F2
case_images: Translocation of EWSR1 was detected by fluorescence in situ hybridization. XL EWSR1 BA (Break Apart Probe, D-5096-100-OG) consists of an orange-labeled probe hybridizing proximal to the EWSR1 gene region at 22q12.1-12.2 and a green-labeled probe hybridizing distal to the EWSR1 gene region at 22q12.2.
case_images: cro-2023-0016-0001-534935_F03.jpg
case_images: PMC10699832_01_cro-2023-0016-0001-534935_F03.jpg
case_images: F3
case_images: Actin ML, Enolase, C-kit, DOG1, CAM5.2, and CKAE1-AE3. An EWSR1 translocation by fluorescence in situ hybridization (Fig. 3) was detected, later confirmed as an EWSR1-ATF1 t(12;22) translocation by next-generation sequencing.
case_images: Cervical CT scans with intravenous contrast. a Radiological image of the cervical mass before trabectedin was started. Cervical mass of 5 cm x 5.4 cm (April 2022). b After 2 cycles with trabectedin. Cervical mass of 5.2 cm (4% increase over baseline) (July 2022). c After 6 cycles of trabectedin were administered. Cervical mass of 3.5 cm (30% decrease over baseline) (September 2022). d Partial response after 8 cycles of treatment with trabectedin was confirmed. Cervical mass of 3 cm (40% decrease over baseline) (December 2022). e Progression disease 10 months later. Cervical mass of 5.5 cm (83.3% increase over baseline) (February 2022).
case_images: cro-2023-0016-0001-534935_F04.jpg
case_images: PMC10699832_01_cro-2023-0016-0001-534935_F04.jpg
case_images: F4
case_images: The following CT scan after eight cycles (December 2022) demonstrated a partial response, which lasted until 10 months when the progression disease was confirmed (Fig. 4).